Marijuana is not the only topic of discussion among Canadians, healthcare has been another popular topic as of late. The nation’s life expectancies are presently among the highest in the world, currently 79 years of age for men and 85 years for women. While this is positive news for the nation’s residents, the impact of the increasing aging population can be intense for healthcare businesses.
The percentage of the total population that is 65 years of age is rapidly increasing, and on average Canadians are having fewer children which results in the percentage of the population under 14 years decrease. This double shift in population has a large effect on all aspects of the healthcare industry, pushing the demand for senior healthcare services through the roof.
As Canadian healthcare industry continues to grow, larger investments are coming into both the private and public sectors. This could present momentous opportunities for Canadian healthcare companies to capitalize on. As novel technologies continue to be developed and new discoveries break the boundaries of innovation, investors continue to seek opportunities within the industry.
Premier Health Group, Inc. (PHGI.CN) is developing innovative health care approaches that combine human skill based expertise with emerging technologies. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI).
Premier Health is currently reviewing a pipeline of strategic acquisitions and scouting new locations, with the expectation to close on two of these opportunities in Q4-2018. The company is specifically targeting acquisitions of clinics, technology and patients in addition to cannabis clinic(s) and partnerships.
The company recently announced selecting Reliq Health Technologies Inc. as its exclusive technology partner. Reliq will be providing Premier’s HealthVue primary care clinics with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients.
ProMetic Life Sciences Inc. (PLI.TO) is a biopharmaceutical corporation with two drug discovery platforms that focus on unmet medical needs. Today, the company announced the completion of a Type C meeting in which the FDA agreed with Prometric’s proposed action plan for the implementation of additional analytical assays and in-process controls related to Ryplazim™ (plasminogen) manufacturing process. Prometic is now finalizing the process performance qualification protocol in anticipation of the start of manufacturing of additional Ryplazim™ conformance lots.
“We are pleased with the positive outcome of the Type C meeting regarding the plan that we submitted in response to the FDA’s list of items outlined in the CMC section of our Ryplazim™BLA,” said Bruce Pritchard, COO, CFO. “As a result of the feedback received, we will now continue with finalizing the remaining steps necessary to proceed with the running of RYPLAZIM™ conformance batches.”
Ravenquest Biomed Inc. (RQB.CN) is a cannabis company with divisions focused upon cannabis production, management services & consulting as well as specialized research & development. RavenQuest maintains a research partnership with Montreal’s McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.
Yesterday the company introduced two distinct flagship brands, both of which will be available to the public beginning October 17th when Canada legalizes adult recreational marijuana use. Throughout its brand development, RavenQuest has remained engaged with Victims of Advertising (VOA), gaining in-depth understanding of target markets and creating brands that appeal to different consumer segments.
Biotech Breakroom is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.
Biotech Breakroom 